The CEO of Bausch Health Companies Inc. is predicting revenue growth this year as the drug maker emerges from a mountain of debt and lawsuits. Joseph Papa said Monday he expects Bausch — formerly known as Valeant Pharmaceuticals — will double revenue from its seven major products to between $150 million (U.S.) and $300 million, driving overall sales growth. Bausch Health’s products include those for eye care that treat conditions ranging from glaucoma to bloodshot eyes. ( EMILE WAMSTEKER / BLOOMBERG NEWS )The so-called “significant seven” include eye care products that treat conditions ranging from glaucoma to bloodshot eyes. Bausch saw a net loss of $3.8 billion in the first nine months of 2018.

Source: thestar January 07, 2019 18:58 UTC